See also this year's filing and all EDGAR filings for this company.
PDF Report 0001772028_2023_Scopus_BioPharma_Inc.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 0.7710821035508951, 'aggregate_val': 20748009, 'exp_sum': 11714877, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 9033132, 'ResearchAndDevelopmentExpense': 2681745, 'remainder_Expenses': 0}} |
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'OperatingExpenses', 'revenue_node': 'RevenueFromContractWithCustomerExcludingAssessedTax', 'net_inc_node': 'ProfitLoss'} |
Graph
Absolute values for 0001772028, Scopus BioPharma Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 390,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 2,265 |
| 3 | remainder_Assets | 0 |
| 4 | LiabilitiesCurrent | 7,454,434 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 9,033,132 |
| 9 | ResearchAndDevelopmentExpense | 2,681,745 |
| 10 | remainder_Expenses | 9,033,132 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 186,749 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 392,265 |
| 1 | Liabilities | 7,454,434 |
| 2 | Expenses | 20,748,009 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | -7,062,169 |
| 5 | NetIncome | -20,748,009 |
| 6 | ComprehensiveNetIncome | -20,654,634 |
| 7 | BaseVar | 14,390,728 |
| 8 | EconomicCapitalRatio | -8.36 |
Edgar->Model Mapping
Feature Distribution
Change over Time
